Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Total Liabilities: 2019-2025

Historic Total Liabilities for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to $345.1 million.

  • Beam Therapeutics' Total Liabilities fell 9.20% to $345.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $345.1 million, marking a year-over-year decrease of 9.20%. This contributed to the annual value of $370.3 million for FY2024, which is 22.60% down from last year.
  • As of Q3 2025, Beam Therapeutics' Total Liabilities stood at $345.1 million, which was up 0.21% from $344.3 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Total Liabilities peaked at $647.7 million during Q4 2021, and registered a low of $270.8 million during Q1 2021.
  • For the 3-year period, Beam Therapeutics' Total Liabilities averaged around $430.9 million, with its median value being $407.2 million (2024).
  • In the last 5 years, Beam Therapeutics' Total Liabilities spiked by 398.21% in 2021 and then dropped by 25.71% in 2024.
  • Over the past 5 years, Beam Therapeutics' Total Liabilities (Quarterly) stood at $647.7 million in 2021, then fell by 6.09% to $608.2 million in 2022, then dropped by 21.35% to $478.4 million in 2023, then fell by 22.60% to $370.3 million in 2024, then decreased by 9.20% to $345.1 million in 2025.
  • Its last three reported values are $345.1 million in Q3 2025, $344.3 million for Q2 2025, and $343.8 million during Q1 2025.